Item 7.01 Regulation FD Disclosure.
On
The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended.
Forward-Looking Statements
This Current Report on Form 8-K and Exhibit 99.1 hereto contain forward-looking
statements that are based on the current expectations and beliefs of Flexion.
Statements regarding matters that are not historical facts are forward-looking
statements, including, but not limited to, statements relating to the potential
completion of the dosing or enrollment of any cohort in the FX201 trial, the
timing of additional data readouts, the potential benefits or clinical efficacy
of FX201, and the possibility and timing of resumption of enrollment and dosing
in the trial. These forward-looking statements are based on management's
expectations and assumptions as of the date of this report and are subject to
numerous risks and uncertainties, which could cause actual results to differ
materially from those expressed or implied by such statements. These risks and
uncertainties include, without limitation, the risk that any clinical trial may
not be completed successfully or at all, as well as other risks and
uncertainties described in Flexion's filings with the
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description 99.1 Presentation ofFlexion Therapeutics, Inc. datedMay 11, 2021 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
--------------------------------------------------------------------------------
© Edgar Online, source